What question did this study set out to answer?

The research aims to assess the safety and efficacy of botulinum toxin in treating symptoms associated with HAM/TSP.

February 12, 2026Journal of Spinal Cord Medicine0 citations

Safety and efficacy of botulinum toxin in Human T-Lymphotropic Virus-1-Associated Myelopathy/Tropical Spastic Paraparesis: A randomized clinical trial

MSMatheus Sales GSGiselle Barbara De Almeida Scaldafferri MAMatheus Henrique Almeida

Key Points

The research aims to assess the safety and efficacy of botulinum toxin in treating symptoms associated with HAM/TSP.
Conducted a randomized clinical trial
Administered botulinum toxin to participants with HAM/TSP
Evaluated spasticity, pain, functioning level, and quality of life post-injection.
Botulinum toxin was found to be safe for participants with HAM/TSP.
The initial dose did not improve symptoms such as spasticity and pain after three months.
Quality of life did not significantly change following treatment.

Abstract

BTA is safe for people with HAM/TSP. However, the first dose of BTA was unable to improve spasticity, pain, functioning level, and quality of life in people with HAM/TSP 3 months after injection. New application strategies of BTA need to be investigated in people with HAM/TSP.

KI fragen

Bookmark

View Full Paper

Cite This Study

Sales et al. (Tue,) studied this question.

synapsesocial.com/papers/698d6dc15be6419ac0d52f6c https://doi.org/https://doi.org/10.1080/10790268.2026.2619808

KI fragen

Bookmark

View Full Paper